Letrozol: Desafíos y Oportunidades en la Región de América Latina 5/18/2022

Los lineamientos sobre la atención para el aborto publicado por la OMS en 2022 incluyen por primera vez un esquema de letrozol y misoprostol como una alternativa medicamentosa en el primer trimestre del embarazo donde no se dispone de la mifepristona. El propósito de este webinario es difundir información sobre letrozol, evidencia sobre su uso para aborto en el primer trimestre, su disponibilidad y costo en algunos países de América Latina donde existe legislación de aborto no punible, y las implicaciones para la atención del aborto.
------------------------------------------------------------------------------------------------------------------------
The updated guideline on abortion care was released in 2022 by the World Health Organization. For the first time, it suggests a combination regimen of letrozole plus misoprostol as an alternative method of early medication abortion for use in settings in which mifepristone is not available. During the webinar, Gynuity Health Projects and Ipas provide insights on letrozole, including evidence on its use for first trimester abortion, its availability and cost in parts of Latin America where abortion is legally permitted, and implications for abortion care.

Held in May 2022, the webinar was hosted by the Reproductive Health Supplies Coalition (RHSC) in collaboration with the Latin American Consortium against Unsafe Abortion (CLACAI). It was held in Spanish, with no interpretation. Credit to RHSC for granting permission to use their recording of the webinar.